Octohydroaminoacridine Succinate — Competitive Intelligence Brief

Octohydroaminoacridine Succinate (Octohydroaminoacridine Succinate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholinesterase inhibitor. Area: Neurology.

phase 3 Acetylcholinesterase inhibitor Acetylcholinesterase Neurology Small molecule

Target snapshot

Octohydroaminoacridine Succinate (Octohydroaminoacridine Succinate) — Shanghai Mental Health Center. Octohydroaminoacridine succinate is a cognitive enhancer that likely increases acetylcholine levels in the brain by inhibiting acetylcholinesterase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Octohydroaminoacridine Succinate TARGET	Octohydroaminoacridine Succinate	Shanghai Mental Health Center	phase 3	Acetylcholinesterase inhibitor	Acetylcholinesterase
Bloxiverz	NEOSTIGMINE	Fresenius Kabi	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2013-01-01
Razadyne	GALANTAMINE	Johnson & Johnson	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2001-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Camptosar	onivyde	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Dyclone	DYCLONINE		marketed	dyclonine	Acetylcholinesterase	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2027-01-06 — Camptosar · 8329213 · US
• 2027-01-06 — Camptosar · 8329213 · Compound · US
• 2028-08-29 — Camptosar · 8147867 · Compound · US
• 2028-08-29 — Camptosar · 8147867 · US
• 2033-06-12 — Camptosar · 9364473 · US
• 2033-06-12 — Camptosar · 9452162 · US
• 2033-06-12 — Camptosar · 9492442 · US
• 2033-06-12 — Camptosar · 9717724 · US
• 2033-06-12 — Camptosar · 9717724 · Method of Use · US
• 2033-06-12 — Camptosar · 9364473 · Method of Use · US
• 2033-06-12 — Camptosar · 12364691 · Method of Use · US
• 2033-06-12 — Camptosar · 11369597 · Method of Use · US
• 2033-06-12 — Camptosar · 9339497 · Method of Use · US
• 2033-06-12 — Camptosar · 9452162 · Method of Use · US
• 2033-06-12 — Camptosar · 9492442 · Method of Use · US
• 2033-06-12 — Camptosar · 10980795 · US
• 2033-06-12 — Camptosar · 11369597 · US
• 2033-06-12 — Camptosar · 9339497 · US
• 2033-06-12 — Camptosar · 10980795 · Method of Use · US
• 2036-08-19 — Camptosar · 11344552 · Method of Use · US
• 2036-10-15 — Camptosar · 10456360 · US
• 2036-10-15 — Camptosar · 10993914 · US
• 2036-10-15 — Camptosar · 12059497 · Formulation · US
• 2036-10-15 — Camptosar · 10456360 · Formulation · US
• 2036-10-15 — Camptosar · 10993914 · Formulation · US

Sponsor landscape (Acetylcholinesterase inhibitor class)

1. Eisai Inc. · 2 drugs in this class
2. Ludwig-Maximilians - University of Munich · 1 drug in this class
3. Neurognostics · 1 drug in this class
4. Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
5. Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
6. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
7. Shanghai Mental Health Center · 1 drug in this class